{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:57:57Z","timestamp":1787504277060,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02480-x","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:37:49Z","timestamp":1760452669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system"],"prefix":"10.1186","volume":"24","author":[{"given":"Chaoyang","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangcheng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"2480_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.hbpd.2021.06.010","volume":"20","author":"AA Khan","year":"2021","unstructured":"Khan AA, Liu ZK, Xu X. Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2021;20:511\u201320.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2480_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"2480_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.iliver.2024.100092","author":"Z Li","year":"2024","unstructured":"Li Z, et al. Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma: a real-world clinical study. iLIVER. 2024;3:100092. https:\/\/doi.org\/10.1016\/j.iliver.2024.100092","journal-title":"iLIVER"},{"key":"2480_CR4","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447\u201358.","journal-title":"Lancet Oncol"},{"key":"2480_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808\u201320.","journal-title":"Lancet Oncol"},{"key":"2480_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24:399\u2013416.","journal-title":"Nat Rev Immunol"},{"key":"2480_CR7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2468-1253(23)00147-4","volume":"8","author":"M Pinter","year":"2023","unstructured":"Pinter M, Scheiner B, Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 2023;8:760\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2480_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585:107\u201312.","journal-title":"Nature"},{"key":"2480_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"2480_CR10","doi-asserted-by":"publisher","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","volume":"3","author":"A Haslam","year":"2020","unstructured":"Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2020;3:e200423.","journal-title":"JAMA Netw Open"},{"key":"2480_CR11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"2480_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"2480_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","volume":"35","author":"SP D'Angelo","year":"2017","unstructured":"D\u2019Angelo SP, et al. Efficacy and safety of Nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35:226\u201335.","journal-title":"J Clin Oncol"},{"key":"2480_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel SJ, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548:537\u201342.","journal-title":"Nature"},{"key":"2480_CR15","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25:1916\u201327.","journal-title":"Nat Med"},{"key":"2480_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44\u201351.","journal-title":"Curr Opin Immunol"},{"key":"2480_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu X, et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22:194.","journal-title":"Mol Cancer"},{"key":"2480_CR18","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1038\/s41467-021-27349-7","volume":"12","author":"Y Deng","year":"2021","unstructured":"Deng Y, et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun. 2021;12:7041.","journal-title":"Nat Commun"},{"key":"2480_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu SS, et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 2021;11:1524\u201341.","journal-title":"Cancer Discov"},{"key":"2480_CR20","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen X, et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell. 2023;186:3903-3920 e3921.","journal-title":"Cell."},{"key":"2480_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"2480_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374.","journal-title":"Annu Rev Immunol"},{"key":"2480_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479\u201385.","journal-title":"Nature"},{"key":"2480_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7:264\u201376.","journal-title":"Cancer Discov"},{"key":"2480_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136.","journal-title":"Nat Genet"},{"key":"2480_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"2480_CR27","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u20139.","journal-title":"Science"},{"key":"2480_CR28","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.1021\/acsnano.3c04507","volume":"18","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. Fluorinated lipid nanoparticles for enhancing mRNA delivery efficiency. ACS Nano. 2024;18:7825\u201336.","journal-title":"ACS Nano"},{"key":"2480_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/endrev\/bnab035","volume":"43","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev. 2022;43:558\u201382.","journal-title":"Endocr Rev"},{"key":"2480_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu X, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693\u20138.","journal-title":"Nature"},{"key":"2480_CR31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835\u201353.","journal-title":"Gastroenterology"},{"key":"2480_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2480_CR33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"2480_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","volume":"42","author":"JD Beck","year":"2024","unstructured":"Beck JD, et al. Long-lasting mRNA-encoded interleukin-2 restores CD8(+) T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell. 2024;42:568-582 e511.","journal-title":"Cancer Cell."},{"key":"2480_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"2480_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202100144","volume":"4","author":"C Meng","year":"2021","unstructured":"Meng C, et al. Virus-mimic mrna vaccine for cancer treatment. Adv Ther. 2021;4:2100144.","journal-title":"Adv Ther"},{"key":"2480_CR37","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao L, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37:1174\u201385.","journal-title":"Nat Biotechnol"},{"key":"2480_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"},{"key":"2480_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.iliver.2022.06.002","volume":"1","author":"J Gao","year":"2022","unstructured":"Gao J, Liu W-R, Tang Z, Fan J, Shi Y-H. Myeloid-derived suppressor cells in cancer. iLIVER. 2022;1:81\u20139.","journal-title":"iLIVER"},{"key":"2480_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"2480_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8:207.","journal-title":"Signal Transduct Target Ther"},{"key":"2480_CR42","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u2013374."},{"key":"2480_CR43","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","volume":"79","author":"M Li","year":"2024","unstructured":"Li M, et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology. 2024;79:560\u201374.","journal-title":"Hepatology"},{"key":"2480_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.coi.2018.03.006","volume":"51","author":"N Aptsiauri","year":"2018","unstructured":"Aptsiauri N, Ruiz-Cabello F, Garrido F. The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses. Curr Opin Immunol. 2018;51:123\u201332.","journal-title":"Curr Opin Immunol"},{"key":"2480_CR45","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2019.12.014","volume":"72","author":"LQ Dong","year":"2020","unstructured":"Dong LQ, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020;72:896\u2013908.","journal-title":"J Hepatol"},{"key":"2480_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41416-021-01400-2","volume":"125","author":"E Schaafsma","year":"2021","unstructured":"Schaafsma E, Fugle CM, Wang X, Cheng C. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br J Cancer. 2021;125:422\u201332.","journal-title":"Br J Cancer"},{"key":"2480_CR47","doi-asserted-by":"publisher","first-page":"8811","DOI":"10.1021\/acsnano.3c11775","volume":"18","author":"S Fang","year":"2024","unstructured":"Fang S, et al. Multiple immunomodulatory strategies based on targeted regulation of proprotein convertase subtilisin\/kexin type 9 and immune homeostasis against hepatocellular carcinoma. ACS Nano. 2024;18:8811\u201326.","journal-title":"ACS Nano"},{"key":"2480_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00995-8","volume":"14","author":"JY Hong","year":"2022","unstructured":"Hong JY, et al. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med. 2022;14:1.","journal-title":"Genome Med"},{"key":"2480_CR49","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41586-022-04772-4","volume":"606","author":"S Badrinath","year":"2022","unstructured":"Badrinath S, et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022;606:992\u20138.","journal-title":"Nature"},{"key":"2480_CR50","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s43018-023-00600-4","volume":"4","author":"EC Lerner","year":"2023","unstructured":"Lerner EC, et al. CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer. 2023;4:1258\u201372.","journal-title":"Nat Cancer"},{"key":"2480_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20:41.","journal-title":"Mol Cancer"},{"key":"2480_CR52","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol. 2023;20:739\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"2480_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301261","volume":"12","author":"L Shi","year":"2023","unstructured":"Shi L, Yang J, Nie Y, Huang Y, Gu H. Hybrid mRNA nano vaccine potentiates antigenic peptide presentation and dendritic cell maturation for effective cancer vaccine therapy and enhances response to immune checkpoint blockade. Adv Healthc Mater. 2023;12:e2301261.","journal-title":"Adv Healthc Mater"},{"key":"2480_CR54","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discov. 2024;23:281\u2013300.","journal-title":"Nat Rev Drug Discov"},{"key":"2480_CR55","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.hbpd.2022.08.003","volume":"21","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Qin LX. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2022;21:420\u20139.","journal-title":"Hepatobiliary Pancreat Dis Int"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02480-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:02:11Z","timestamp":1769839331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02480-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2480"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02480-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The published Supplementary Material 2 contained some highlighted markings and was replaced with the correct, publication-ready file to ensure clarity for readers.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the ethical principles outlined in the Declaration of Helsinki and received approval from the Clinical Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (2022\u2013161). All animal studies followed the protocols approved by the Institutional Animal Care and Use Committee at The First Affiliated Hospital, Zhejiang University School of Medicine (2023\u2013536). Every procedure complied the ethical regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}